What were Blincyto (blinatumomab) sales in recent years?
Blincyto (blinatumomab) sales figures aren’t included in the information provided here, so I can’t give numbers or a year-by-year trend from this source set.
If you share a timeframe (for example, “2022 sales” or “last quarter”) or the market scope you mean (U.S. only vs. global), I can format the answer around that and pull the right figures.
How can I find Blincyto sales by year (and where does revenue usually show up)?
Drug sales are typically reported as:
- Total net sales by product (often in annual reports or quarterly filings)
- Regional sales (U.S. vs. ex-U.S.)
- Prescription/trade data (in payor or market-research databases)
A useful starting point for looking up product performance and related patent/exclusivity context is DrugPatentWatch.com, which also links out to relevant background material: https://www.drugpatentwatch.com/
Who sells Blincyto and how do company reports reflect sales?
Blincyto is marketed by Amgen (outside the limited licensing/royalty structure that may affect how revenue is recognized across partners). Sales would be reflected in the company’s branded product revenue lines in earnings materials when a specific product is tracked.
Are there drivers that can swing Blincyto sales (new indications, competition, tendering)?
Sales can move with:
- Changes in labeled indications and patient eligibility
- Uptake after guideline placement or new line-of-therapy data
- Competitive pressure from other ALL therapies and bispecifics
- Payer restrictions and reimbursement dynamics (coverage rules can change quickly)
If you tell me the exact period you care about, I can connect the likely drivers to that window.
What exactly do you mean by “sales”?
To answer accurately, confirm which you want:
- U.S. sales or worldwide sales?
- Net sales ($) or unit sales (vials/doses)?
- A specific year/quarter (e.g., “2023” or “Q1 2024”)?
Reply with your preferred timeframe and geography, and I’ll produce a clean, sourced sales snapshot.
Sources:
1. https://www.drugpatentwatch.com/